Tidal Investments LLC Sells 1,567 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Tidal Investments LLC decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 13.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 9,705 shares of the biotechnology company’s stock after selling 1,567 shares during the period. Tidal Investments LLC’s holdings in United Therapeutics were worth $3,424,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Wealthfront Advisers LLC increased its holdings in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Norges Bank acquired a new position in shares of United Therapeutics during the 4th quarter worth about $151,764,000. FMR LLC increased its stake in shares of United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after acquiring an additional 393,777 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in shares of United Therapeutics by 1,325.5% in the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock valued at $72,085,000 after acquiring an additional 189,967 shares during the last quarter. Finally, AustralianSuper Pty Ltd raised its position in shares of United Therapeutics by 577.1% in the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after acquiring an additional 161,751 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond Dwek sold 4,000 shares of United Therapeutics stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the completion of the transaction, the director now directly owns 1,750 shares of the company’s stock, valued at approximately $497,962.50. This trade represents a 69.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,500 shares of company stock worth $17,054,780 in the last 90 days. Corporate insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on UTHR. HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Morgan Stanley upped their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research report on Thursday, May 1st. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. Wells Fargo & Company reissued an “equal weight” rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Finally, Bank of America upgraded United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price target for the company in a report on Monday, April 21st. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $392.00.

United Therapeutics Price Performance

United Therapeutics stock opened at $309.68 on Thursday. The company has a market cap of $13.97 billion, a price-to-earnings ratio of 13.60, a P/E/G ratio of 0.97 and a beta of 0.58. The firm has a 50-day moving average of $300.05 and a 200-day moving average of $339.31. United Therapeutics Co. has a one year low of $264.33 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.17 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.